Harvard Pilgrim picks Repatha

Regional insurance company Harvard Pilgrim Health Care Inc. granted Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) exclusive preferred status on its formulary in exchange for undisclosed discounts on the lipid-lowering drug.

Additionally, the parties agreed to a pay-for-performance deal whereby Amgen will provide Harvard Pilgrim with an "enhanced discount" if the reduction in LDL levels for Harvard Pilgrim members is less than what was observed during clinical trials. The size of the discount is not disclosed. ...